WallStSmart

The Ensign Group Inc (ENSG)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 254% more annual revenue ($19.43B vs $5.49B). ENSG leads profitability with a 6.9% profit margin vs 4.8%. FMS appears more attractively valued with a PEG of 0.74. ENSG earns a higher WallStSmart Score of 61/100 (C+).

ENSG

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.15

FMS

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGSignificantly Overvalued (-39.8%)

Margin of Safety

-39.8%

Fair Value

$151.57

Current Price

$173.91

$22.34 premium

UndervaluedFair: $151.57Overvalued
FMSUndervalued (+68.5%)

Margin of Safety

+68.5%

Fair Value

$76.29

Current Price

$22.20

$54.09 discount

UndervaluedFair: $76.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.3%8/10

17.3% revenue growth

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
12.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.748/10

Growing faster than its price suggests

Areas to Watch

ENSG2 concerns · Avg: 3.5/10
P/E RatioValuation
26.7x4/10

Moderate valuation

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

FMS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 17.3% demonstrates continued momentum. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.74 suggests the stock is reasonably priced for its growth.

Bear Case : ENSG

The primary concerns for ENSG are P/E Ratio, Profit Margin.

Bear Case : FMS

The primary concerns for FMS are Revenue Growth, Altman Z-Score, Return on Equity. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENSG profiles as a growth stock while FMS is a value play — different risk/reward profiles.

FMS carries more volatility with a beta of 0.83 — expect wider price swings.

ENSG is growing revenue faster at 17.3% — sustainability is the question.

FMS generates stronger free cash flow (620M), providing more financial flexibility.

Bottom Line

ENSG scores higher overall (61/100 vs 58/100) and 17.3% revenue growth. FMS offers better value entry with a 68.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?